Revenue Recognition (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Financing Receivable, Past Due [Line Items]
Total contract revenue		$ 13,614	$ 9,560	$ 31,687	$ 41,199
Pharmaceutical Development Services [Member]
Financing Receivable, Past Due [Line Items]
Total contract revenue		5,111	187	5,941	11,342
Pharmaceutical Development Services [Member] | Licensing Agreements [Member]
Financing Receivable, Past Due [Line Items]
Total contract revenue	[1]	5,103	176	5,235	10,786
Pharmaceutical Development Services [Member] | Other Intangible Assets [Member]
Financing Receivable, Past Due [Line Items]
Total contract revenue		$ 8	$ 11	706	$ 556
Enteris License Agreement [Member]
Financing Receivable, Past Due [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized				$ 5,000,000

[1] $5.0 million of milestone revenue related to Enteris’s License Agreement with Cara was received during the nine months ended September 30, 2022.